Fapon Biotech delivers antigen diagnostic solutions to control monkeypox outbreak in Africa

image credit- shutterstock

As the World Health Organization (WHO) declared monkeypox outbreak as a public health emergency of international concern (PHEIC) on Aug 14, China’s Fapon Biotech announced provision of antigen diagnostic products addressing this emerging threat.

In 2023, the increased global circulation of the monkeypox virus heightened the demand for diagnostics, altogether demonstrating a clear need for simplified, automated, and accessible assay that are available outside laboratories. In response to the increased global spread of the monkeypox virus in 2023, WHO specified a target product profile designed for decentralized use, including in community settings to enhance access to quality-assured, accurate, and accessible monkeypox diagnostics. This measure has encouraged more IVD companies to develop POCT products, that are more convenient and accessible for screening and diagnosis in rural environments and areas with limited healthcare resources.

Fapon's products for monkeypox detection have high sensitivity, high specificity, and demonstrate no cross-reactivity with non-OPXVs such as the varicella-zoster virus. Fapon Biotech's solutions have been developed to offer more effective and accessible testing options, particularly for low- and middle-income countries and regions, thereby facilitating rapid diagnosis in such areas.